First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Clear Cell Renal Cell Cancer|Non-Small-Cell Lung Cancer|Triple Negative Breast Neoplasms|Squamous Cell Cancer of Head and Neck|Small Cell Lung Cancer|Gastroesophageal Cancer|Melanoma|Cervical Cancer|Advanced Solid Tumours
Interventions: DRUG: AZD8701|BIOLOGICAL: Durvalumab
Sponsor: AstraZeneca